Data Sheet (Cat.No.T10409)

TargetMol

ATX inhibitor 5

Chemical Properties



CAS No. : 2402772-45-4

Formula: C22H18ClF3N6O

Molecular Weight: 474.87

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.
Targets(IC50)	PDE
In vitro	ATX inhibitor 5 (10 μM) successfully suppresses collagen content induced by TGF-β.[1]
In vivo	ATX inhibitor 5 (20-40 mg/kg/d, p.o., two weeks) significantly reduces CCl4-induced hepatic fibrosis levels.[1]

Solubility Information

Solubility	DMSO: 225 mg/mL (473.81 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.95 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1058 mL	10.5292 mL	21.0584 mL
5 mM	0.4212 mL	2.1058 mL	4.2117 mL
10 mM	0.2106 mL	1.0529 mL	2.1058 mL
50 mM	0.0421 mL	0.2106 mL	0.4212 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

JiangN, et al. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.Eur J Med Chem. 2020 Feb 1;187:111904.